Abstract
Purpose: Since there are currently no data available from a prospective trial, the primary objective of this prospective study was to investigate whether the rate of R0-liver resections without morbidity would be at least 50 % in patients with neoadjuvant chemotherapy for colorectal liver metastases.
Patients and methods: 42 patients were treated with a biweekly FOLFOX regimen. Chemotherapy consisted of a 2-hour infusion of folinic acid (FOL) 500 mg/m2 , followed by a 24-hour infusion of 5- fluorouracil (F) 2 000 mg/m2 daily for two days. Oxaliplatin (OX) 85 mg/m2 was given simultaneously with FOL. Treatment allocation was randomized with either 3 or 6 cycles for the final 30 patients. A liver resection was performed 2 to 5 weeks after the final infusion.
Results: An objective response was observed in 20 of 42 patients (response rate was 27 % higher after 6 cycles). Liver resection (R0) could be performed in 34 patients. Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection). Liver failure and persistent biliary fistula were the most frequently documented complications. There was no relevant difference in safety criteria between 3 and 6 applications.
Conclusion: The use of neoadjuvant chemotherapy in resectable liver metastases induced significant remissions without increasing morbidity. The rate of severe complications and cases of no R0-resection in this study was 31 % and was with that significantly lower than 50 % (95 % CI 17.6 %-47.1 %). The risk to the patient is therefore acceptable when undergoing neoadjuvant treatment in a prospective intergroup trial.
Zusammenfassung
Ziel der Untersuchung: Derzeit existieren keine prospektiven Daten zur neoadjuvanten Chemotherapie vor Resektion kolorektaler Lebermetastasen. Primäres Studienziel war es deshalb in dieser prospektiven Studie zu überprüfen, ob bei dieser Therapie eine Rate von mindestens 50 % R0-Resektionen ohne Morbidität erzielt werden kann.
Methodik: 42 Patienten wurden mit einem 14-tägigen FOLFOX-Regime behandelt. Die Chemotherapie beinhaltete eine 2-h-Infusion mit Folinsäure (FOL) 500 mg/m2 /d, gefolgt von einer 24-h-Infusion mit 5-Fluorouracil (F) 2 000 mg/m2 /d jeweils über zwei Tage. Oxaliplatin (OX) 85 mg/m2 wurde simultan mit FOL am ersten Therapietag verabreicht. Die letzten 30 Patienten wurden in entweder 3 oder 6 Zyklen der Chemotherapie randomisiert. Die Leberresektion wurde 2 bis 5 Wochen nach der letzten Chemotherapie durchgeführt.
Ergebnisse: Ein objektives Ansprechen wurde in 20 von 42 Patienten beobachtet. Bei der Durchführung von 6 Zyklen war die Ansprechrate um 27 % höher. 34 Patienten konnten R0-leberreseziert werden. Über postoperative Komplikationen wurde bei 14 Patienten (13 innerhalb von 30 Tagen nach Resektion) und über schwere Komplikationen in 5 Fällen (inklusive 2 Todesfälle nach erweiterter Resektion) berichtet. Leberversagen und persistierende Gallefisteln wurden am häufigsten dokumentiert. Relevante Unterschiede hinsichtlich der Sicherheitskriterien zwischen 3 und 6 Applikationen ergaben sich nicht.
Diskussion: Eine neoadjuvante Chemotherapie bei resektablen Lebermetastasen führt zu einer signifikanten Remission ohne Anstieg der Morbidität nach Resektion. Die Rate an schweren Komplikationen und R1- oder R2-Resektionen betrug 31 % und war damit signifikant niedriger als 50 % (95 % CI 17,6 %-47,1 %). Das Risiko der Durchführung einer neoadjuvanten Chemotherapie innerhalb einer prospektiven Intergroup-Studie ist somit für den Patienten akzeptabel.
Key words
Neoadjuvant chemotherapy - liver metastases - colorectal
Schlüsselwörter
Neoadjuvante Chemotherapie - Lebermetastasen - Kolorektal
References
1
Adam R, Avisar E, Ariche A. et al .
Five year survival following hepatic resection after neoadjuvant therapy of non resectable colorectal liver metastases.
Ann Surg Oncol.
2001;
8
347-353
2
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference .
definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
Critical Care Medicine.
1992;
20
864-867
3
Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L.
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.
Ann Surg.
1996;
224
509-522
4
Black R J, Bray F, Ferlay J, Parkin D M.
Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.
Cancer.
1997;
33
1075-1079
5
Bolder U, Brune A, Schmidt S, Tacke J, Jauch K W, Lohlein D.
Preoperative assessment of mortality risk in hepatic resection by clinical variables: a multicenter analysis.
Liver Transplantation and Surgery.
1999;
5
227-237
6
Broadwater R J, Edwards M J, Kuglen C Hortobagyi G N, Ames F C, Balch C M.
Mastectomy following preoperative chemotherapy: Strict operative criteria control operative morbidity.
Ann Surg.
1991;
213
126-129
7
Buzdar A U, Singletary S E, Theriault R L, Booser D J, Valero V, Ibrahim N, Smith T L, Asmar L, Frye D, Manuel N, Kau S W, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi G N.
Prospective evaluation of Paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
J Clin Oncol.
1999;
17
3412-3417
8
Cady B, Monson D O, Swinton N W.
Survival of patients after colonic resection for carcinoma with simultaneous liver metastases.
Surg Gynecol Obstet.
1970;
131
697-700
9
Cornell K, Waters D J.
Impaired wound healing in the cancer patient: effects of cytotherapy and pharmacologic modulation by growth factors.
Vet Clin North Am Small Anim Pract.
1995;
25
111-131
10
Crohnert T U, Rau H G, Buttler E, Hernandez-Richter T, Sauter G, Reuter C, Schildberg F W.
Preoperative risk assessment of hepatic resection for malignant disease.
World J Surg.
1997;
21
396-401
11
Danforth DN J r, Lippmann M E, McDonald.
Bader J, Egan E, Lampert M, Steinberg SM, Swain SM. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.
Am Surg.
1990;
56
6-11
12
de Gramont A, Tournigand C, Louvet C, Andre T, Molitor J L, Raymond E, Moreau S, Vignoud J, Le Bail N, Krulik M.
Oxaliplatine, acide folinique et 5-fluorouracile (folfox) en seconde ligne thérapeutique du cancer colorectal métastasé.
Rev Méd Interne.
1997;
18 (10)
769-775
13
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment.
J Clin Oncol.
2000;
18
2938-2947
14
Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F, Bonalumi M G.
Morbidity and mortality after hepatic resection of metastases from colorectal cancer.
British Journal of Surgery.
1995;
82
377-381
15 Edmondson H A, Peters R L. Neoplasms of the liver. In: Schiff L, Schiff EL (eds). Anonymous Disease of the Liver. Philadelphia PA, JB Lippincott 1987; 1103
16
Finn D, Steele G J r, Osteen R T, Wilson A E.
Morbidity and mortality after surgery in patients with disseminated or locally advanced cancer receiving systemic chemotherapy.
J Surg Oncol.
1980;
13
237-244
17
Giachetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset J L, Levi F.
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Annals of Oncology.
1999;
10
663-669
18
Gunduz N, Fisher B, Saffer E A.
Effect of surgical removal on the growth and kinetics of residual tumor.
Cancer Res.
1979;
39
3861-3865
19 Jaeck D, Nordlinger B, Schaal J C. Methods of surgical excision. In: Nordlinger B, Jaeck D (eds). Treatment of hepatic metastases of colorectal cancer. Springer-Verlag, B. France 1992; 87
20
Jarnaging W R, Fong Y, Ky A, Schwartz L H, Paty P B, Cohen A M, Blumgart L H.
Liver resection for metastatic colorectal cancer.
J Am Coll Surg.
1999;
188
33-42
21
Jarnagin W R, Conlon K, Bodniewicz J, Dougherty E, DeMatteo R P, Blumgart L H, Fong Y.
A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases.
Cancer.
2001;
91
1121-1128
22
Kavolius J, Fong Y, Blumgart L H.
Surgical resection of metastatic liver tumors.
Surg Oncol Clin N Am.
1996;
5
337-352
23
Kemeny N, Huang Y, Cohen A M, Shi W, Conti J A, Brennan M F, Bertino J R, Turnbull A D, Sullivan D, Stockman J, Blumgart L H, Fong Y.
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
N Engl J Med.
1999;
341
2039-2048
24
Lambert L A, Colacchio T A, Barth R J.
Interval hepatic resection of colorectal metastases improves patient selection.
Arch Surg.
2000;
135
473-479
25
Lawrence W T, Norton J A, Harvey A K, Gorschboth C M, Talbot T L, Grotendorst G R.
Doxorubicin-induced impairment of wound healing in rats.
J Natl Cancer Inst.
1986;
76
119-126
26
Lévi F, Misset J L, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel J P, Kunstlinger F, Lecouturier S, Descorps-Declere A.
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer.
Cancer.
1992;
69
893-900
27
Lorenz M, Müller H -H, Schramm H, Gassel H J, Rau H G, Ridwelski K, Hauss J, Stieger R, Jauch K W, Bechstein W O, Encke A.
Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer.
Ann Surg.
1998;
228
756-762
28
Lorenz M, Hochmuth K, Müller H H.
Letter to the Editor. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
N Engl J Med.
2000;
342
1525-1526
29
McMasters K M, Hunt K H.
Neoadjuvant chemotherapy, locally advanced breast cancer and quality of life.
J Clin Oncol.
1999;
17
441-446
30
Nagorney D M, van Heerden J A, Ilstrup D M, Doherty D, Ikai I, Yamaoka Y, Regimbeau J M, Belghiti J, Curley S A, Ellis L M, Vauthey J N.
Primary hepatic malignancy: surgical management and determinants of survival.
Surgery.
1989;
106
740-749
31 Nordlinger B, Jaeck D, Guiguet M. Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordlinger B, Jaeck D (eds). Treatment of hepatic metastases of colorectal cancer. Springer-Verlag, B. France 1992; 129
32
Nordlinger B, Guiguet M, Vaillant J C, Balladur P, Boudjema K, Bachellier P, Jaeck D.
Surgical resection of colorectal carcinoma metastases to the liver. Association Française de Chirurgie.
Cancer.
1996;
77
1254-1262
33
Pace R F, Blenkharn J I, Edwards WJ Orloff M, Blumgart L H, Benjamin I S.
Intra-abdominal sepsis after hepatic resection.
Ann Surg.
1989;
209
302-306
34
Parker S L, Tong T, Bolden S, Wingo P A.
Cancer Statistics 1997.
CA Cancer J Clin.
1997;
47
5-27
35
Rees M, Plant G, Wells J, Bygrave S.
One hundred and fifty hepatic resections: evolution of technique towards bloodless surgery.
Brit J Surgery.
1996;
83
1526-1529
36
Saltz J B, Cox J V, Blanke C, Rosen L S, Fehrenbacher L, Moore M J, Maroun J A, Ackland S P, Locker P K, Pirotta N, Elfring G L, Miller L L.
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
N Engl J Med.
2000;
34
905-914
37
Steele G, Bleday R, Mayer R J, Lindblad A, Petrelli N, Weaver D.
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: gastrointestinal tumor study group protocol 6 584.
J Clin Oncol.
1991;
9
2078-2079
38
Taylor I, Mullee M A, Campbell M J.
Prognostic index for the development of liver metastases in patients with colorectal cancer.
Br J Surg.
1990;
77
499-501
39
Vauthey J N.
Liver imaging: a surgeon’s perspective.
Radiol Clin North Am.
1998;
36
63-67
40
Vetto J T, Hughes K S, Rosenstein R, Sugarbaker P H.
Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma.
Dis Colon Rectum.
1990;
33
408-412
41
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio- Preiser C M, Napier J, Horne C H, Lopez M J.
Haematogoneous metastatic patterns in colonic carcinoma: an analysis of 1 541 necropsies.
J Pathol.
1986;
150
195-203
42
Weitz J, Koch M, Kienle P, Schrodel A, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M.
Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer.
Ann Surg.
2000;
232
66-72
43
Wiezer M J, Meijer C, Sietses C, Prins H A, Cuesta M A, Beelen R H, Meijer S, van Leeuwen P A.
Bactericidal/permeability increasing protein preserves leukocyte functions after major liver resection.
Ann Surg.
2000;
232
208-215
44 World Health Organization: handbook for reporting results of cancer t reatment. WHO Offset Publication N0.48. Geneva WHO 1979
45
Zadavski K E, Lee Y TM.
Liver metastases from colorectal carcinoma: incidence, respectability and survival results.
Ann Surg.
1994;
60
929-932
Prof. Dr. Matthias Lorenz
Department of General and Vascular Surgery
Johann-Wolfgang-Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Phone: 0 69/6 31 43 46
Fax: 0 69/6 31 43 47
Email: gog@em.uni-frankfurt.de